Lixte Biotechnology Enters Material Definitive Agreement
Ticker: LIXT · Form: 8-K · Filed: Dec 23, 2025 · CIK: 1335105
Sentiment: neutral
Topics: material-definitive-agreement, filing-update
TL;DR
Lixte Biotech signed a big deal on 12/17/25. Details TBD.
AI Summary
Lixte Biotechnology Holdings, Inc. announced on December 17, 2025, that it entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offices in Boca Raton, Florida, filed this 8-K report on December 23, 2025. The filing does not provide specific details about the agreement or any associated dollar amounts.
Why It Matters
This filing indicates a significant new contract or partnership for Lixte Biotechnology, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing regarding the material definitive agreement introduces uncertainty about its nature and potential impact.
Key Players & Entities
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. (company) — Registrant
- December 17, 2025 (date) — Date of earliest event reported
- December 23, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- Boca Raton, Florida (location) — Principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by Lixte Biotechnology Holdings, Inc.?
The filing states that Lixte Biotechnology Holdings, Inc. entered into a material definitive agreement on December 17, 2025, but does not provide specific details about its nature.
When was this 8-K report filed with the SEC?
This 8-K report was filed on December 23, 2025.
What is Lixte Biotechnology Holdings, Inc.'s state of incorporation?
Lixte Biotechnology Holdings, Inc. is incorporated in Delaware.
Where are Lixte Biotechnology Holdings, Inc.'s principal executive offices located?
The principal executive offices of Lixte Biotechnology Holdings, Inc. are located at 433 Plaza Real, Suite 275, Boca Raton, Florida 33432.
Does the filing specify any dollar amounts related to the material definitive agreement?
No, the filing does not specify any dollar amounts related to the material definitive agreement.
Filing Stats: 1,381 words · 6 min read · ~5 pages · Grade level 11.3 · Accepted 2025-12-23 16:00:53
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share LIXT The NASDAQ Stock Mar
- $500,000 — d to the Expanded Study as follows; (i) $500,000 upon Initiation of the first Pivotal Cl
Filing Documents
- form8-k.htm (8-K) — 48KB
- ex10-1.htm (EX-10.1) — 5KB
- ex10-2.htm (EX-10.2) — 8KB
- ex99-1.htm (EX-99.1) — 15KB
- ex10-1_001.jpg (GRAPHIC) — 694KB
- ex10-1_002.jpg (GRAPHIC) — 234KB
- ex10-1_003.jpg (GRAPHIC) — 392KB
- ex10-1_004.jpg (GRAPHIC) — 427KB
- ex10-1_005.jpg (GRAPHIC) — 452KB
- ex10-1_006.jpg (GRAPHIC) — 258KB
- ex10-2_001.jpg (GRAPHIC) — 539KB
- ex10-2_002.jpg (GRAPHIC) — 594KB
- ex10-2_003.jpg (GRAPHIC) — 498KB
- ex10-2_004.jpg (GRAPHIC) — 188KB
- ex10-2_005.jpg (GRAPHIC) — 158KB
- ex10-2_006.jpg (GRAPHIC) — 590KB
- ex10-2_007.jpg (GRAPHIC) — 659KB
- ex10-2_008.jpg (GRAPHIC) — 559KB
- ex10-2_009.jpg (GRAPHIC) — 665KB
- ex10-2_010.jpg (GRAPHIC) — 69KB
- 0001493152-25-028999.txt ( ) — 9857KB
- lixt-20251217.xsd (EX-101.SCH) — 3KB
- lixt-20251217_lab.xml (EX-101.LAB) — 33KB
- lixt-20251217_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 23, 2025 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Registrant) By: /s/ Geordan Pursglove Geordan Pursglove Chairman of the Board and Chief Executive Officer